334 related articles for article (PubMed ID: 23483435)
1. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.
Yang P; Wang Y; Peng X; You G; Zhang W; Yan W; Bao Z; Wang Y; Qiu X; Jiang T
J Neurooncol; 2013 Jun; 113(2):259-66. PubMed ID: 23483435
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of prognostic factors for survival in
elderly patients with glioma].
Liu J; Lou M; Ji P; Li C; Feng F; Li B; Xu M; Gao G; Qu Y; Wang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):403-409. PubMed ID: 29774877
[TBL] [Abstract][Full Text] [Related]
3. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
[TBL] [Abstract][Full Text] [Related]
4. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
5. [Survival of newly diagnosed malignant glioma patients on combined modality therapy].
Yang QY; Shen D; Sai K; Jiang XB; Ke C; Zhang XH; Mou YG; Chen ZP
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(1):8-10. PubMed ID: 23578444
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas.
Gan Y; Zhou X; Niu X; Li J; Wang T; Zhang H; Yang Y; Liu Y; Mao Q
World Neurosurg; 2019 Jul; 127():e261-e267. PubMed ID: 30898756
[TBL] [Abstract][Full Text] [Related]
7. Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas.
Wang C; Liu S; Peng L; Zhang K; Li W; Zhang H; Luan Y; Li P; Hu X
BMC Cancer; 2020 Jun; 20(1):591. PubMed ID: 32580723
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
Hua L; Zhu H; Li J; Tang H; Kuang D; Wang Y; Tang F; Chen X; Zhou L; Xie Q; Gong Y
J Neurosurg; 2018 Jun; 128(6):1698-1706. PubMed ID: 28820306
[TBL] [Abstract][Full Text] [Related]
10. High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients.
Xu T; Qin R; Zhou J; Yan Y; Lu Y; Zhang X; Fu D; Lv Z; Li W; Xia C; Hu G; Ding X; Chen J
PLoS One; 2012; 7(10):e48415. PubMed ID: 23119009
[TBL] [Abstract][Full Text] [Related]
11. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute.
Turkoglu E; Gurer B; Sanli AM; Dolgun H; Gurses L; Oral NA; Donmez T; Sekerci Z
Clin Neurol Neurosurg; 2013 Dec; 115(12):2508-13. PubMed ID: 24225484
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants.
Alimohammadi E; Bagheri SR; Sadeghsalehi A; Rizevandi P; Rezaie Z; Abdi A
Acta Neurol Belg; 2020 Dec; 120(6):1341-1350. PubMed ID: 31222512
[TBL] [Abstract][Full Text] [Related]
16. Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.
Youland RS; Schomas DA; Brown PD; Nwachukwu C; Buckner JC; Giannini C; Parney IF; Laack NN
Neuro Oncol; 2013 Aug; 15(8):1102-10. PubMed ID: 23814262
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma.
Shee K; Chambers M; Hughes EG; Almiron DA; Deharvengt SJ; Green D; Lefferts JA; Andrew AS; Hickey WF; Tsongalis GJ
J Neurooncol; 2020 Jul; 148(3):473-480. PubMed ID: 32583303
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
